Hirayama, Atsushi

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome

Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 565

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 338

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid (RESPECT-EPA)

Miyauchi, K., Iwata, H., Nishizaki, Y., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2024) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 92

Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study

Nishizaki, Y., Miyauchi, K., Iwata, H., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2023) · American Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 40